HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 17 March 2016

Consultation on Specialised Services

NHS England has launched public consultations on a further two waves of new policies and service specifications for specialised services.

Wave 4

Service Specifications
  • Specialised Respiratory Services (adult) – Severe Asthma
  • Specialised Vascular Services (Adults)

Clinical Commissioning Policies
  • Pegvisomant for acromegaly as a third-line treatment (adults)
  • Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy
  • Cinacalcet for complex primary hyperparathyroidism
  • Teriparatide for the treatment of osteogenesis imperfecta (Adults)
  • Pasireotide for acromegaly as third-line treatment (adults)
  • Rituximab for immunoglobulin G4-related disease (IgG4-RD)
  • Immune Tolerance Induction (ITI) for haemophilia A (all ages)

Wave 5

Clinical Commissioning Policies

  • Urethroplasty for benign urethral strictures in adult men
  • Surgical sperm retrieval for male infertility
  • Penile prosthesis surgery for end stage erectile dysfunction
  • Fampridine for multiple sclerosis (adults)
  • Ziconotide (intrathecal delivery) for chronic refractory cancer pain
  • Autologous chondrocyte implantation for osteochondral lesions of the talus (adults)
  • Bone morphogenetic protein-2 in spinal fusion
  • Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex